Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
5 drugs across 2 manufacturers|1 Generic,4 Brand
The Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class contains 5 NDCs from 2 manufacturers (1 generic, 4 brand), at an average NADAC of $815.37 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
5
1G / 4B
Manufacturers
2
Avg $815.3688/unit
Avg 7d Change
-0.04%
Across 2 drugs with changes
7d Activity
of 5 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
2 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
HARVONI 90-400 MG TABLET LEDIPASVIR and SOFOSBUVIR | $1098.9375 per EA | — |
SOVALDI 400 MG TABLET SOFOSBUVIR | $975.3000 per EA | — |
EPCLUSA 400 MG-100 MG TABLET Velpatasvir and Sofosbuvir | $865.8921 per EA | -0.06% |
VOSEVI 400-100-100 MG TABLET SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR | $858.6884 per EA | — |
SOFOSBUVIR-VELPATASVIR 400-100 Velpatasvir and Sofosbuvir | $278.0258 per EA | -0.01% |
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Gilead Sciences, Inc. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Velpatasvir and Sofosbuvir market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class?
The Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class contains 5 NDCs from 2 manufacturers — 1 generic and 4 brand products.
What is the average price of Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor drugs?
The average NADAC for the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class is $815.3688 per unit across 5 NDCs.
Is generic cheaper than brand in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $278.0258, versus $949.7045 for brand — brand products average about 3.4× the generic price.
Which manufacturers make Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor drugs?
2 manufacturers make drugs in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class. Ranked by number of NDCs, the largest are Gilead Sciences, Inc. (4), Asegua Therapeutics LLC (1).
How has Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor pricing changed recently?
Over the past 7 days, 0 NDCs in this class rose and 2 fell, with a class-wide average change of -0.0%.